Future efforts should focus on designing rigorous human trials to evaluate the therapeutic efficacy of enhancing LRP‐1 expression and modulating pericyte function in AD patients, as well as to determine their potential as clinical treatment targets. Here, LRP1 is linked to Alzheimer disease.